Supernus Pharmaceuticals Inc. (S49)
XSTU 
Summary
S49 Chart
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. ( SUPN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Jack Khattar - Founder, President, CEO, Secretary & Director Timothy Dec - Senior VP & CFO Conference Call Participants Peter Vozzo - Westwicke Partners, LLC Lin Tsai - Jefferies LLC, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division David Amsellem - Piper Sandler & Co., Research Division Pavan Patel - BofA Securities, Research Division Stacy Ku - TD Cowen, Research Division Presentation Operator " Jack Khattar Founder, President, CEO, Secretary & Director " Timothy Dec Senior VP & CFO " Peter Vozzo Westwicke Partners, LLC " Lin Tsai Jefferies LLC, Research Division " Jefferies LLC, Research Division Annabel Samimy Stifel, Nicolaus & Company, Incorporated, Research Division " Stifel, Nicolaus & Company, Incorporated, Research Division David Amsellem Piper Sandler & Co., Research Division " Piper Sandler & Co., Research Division Pavan Patel BofA Securities, Research Division " BofA Securities, Research Division Stacy Ku TD Cowen, Research Division " TD Cowen, Research Division Operator Good afternoon, and welcome to the Supernus Pharmaceuticals Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $1.06 per share a year ago.
Supernus Pharmaceuticals Inc. (S49) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Supernus Pharmaceuticals Inc. ever had a stock split?
Supernus Pharmaceuticals Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Jack A. Khattar CEO | XSTU Exchange | US8684591089 ISIN |
| US Country | 674 Employees | - Last Dividend | - Last Split | 1 May 2012 IPO Date |
Overview
Supernus Pharmaceuticals, Inc. is a biopharmaceutical enterprise dedicated to addressing the complex challenges of central nervous system (CNS) diseases within the United States. Since its inception in 2005, based in Rockville, Maryland, Supernus has committed itself to the development and commercialization of innovative and effective treatments aimed at improving the quality of life for patients suffering from a broad range of CNS conditions. Its strategic approach involves a comprehensive research and development program, coupled with extensive clinical trials to ensure the efficacious and safe application of its products.
Products and Services
- Trokendi XR: An extended-release formulation of topiramate, designed to treat epilepsy and prevent migraine headaches by delivering a steady dosage of medication over an extended period.
- Oxtellar XR: An extended-release version of oxcarbazepine that serves as monotherapy for partial-onset seizures in both adults and children aged 6 to 17 years, streamlining the management of epilepsy with once-daily dosing.
- Qelbree: A novel, non-stimulant medication approved for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older, offering a new therapeutic option without the same abuse potential as traditional stimulant drugs.
- APOKYN: Provides acute, intermittent treatment of hypomobility or 'off' episodes in patients with advanced Parkinson's Disease (PD), contributing significantly to the management of mobility-related fluctuations experienced by these patients.
- XADAGO: A medication used alongside levodopa/carbidopa in PD patients experiencing 'off' episodes, enhancing the control of motor symptoms and improving patients' quality of life.
- MYOBLOC: A Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults, showcasing the importance of targeted therapy in managing complex motor disorders.
- GOCOVRI: Approved for treating dyskinesia in patients with PD, this medication contributes to the broader effort to manage the side effects associated with long-term PD treatment.
- Osmolex ER: This extended-release medication is designed for the treatment of Parkinson's disease and drug-induced extrapyramial reactions in adult patients, illustrating the ongoing need for innovative PD management strategies.
- In development, Supernus boasts a portfolio of promising candidates, including SPN-830, a late-stage drug/device combination for 'off' episodes in PD; and SPN-817, a novel, first-in-class selective acetylcholinesterase inhibitor in Phase II trials for epilepsy. Other candidates like SPN-820, targeting resistant depression, and SPN-443 as well as SPN-446 and SPN-448 in earlier stages for ADHD/CNS and narcolepsy treatment, respectively, illustrate the company’s dedication to expanding its array of CNS therapies.
Contact Information
